TBK1 binding protein 1Genealiases: ProSAPiP2 · SINTBAD
Q-omics provides the consensus-scored TBKBP1 profile across patient tissues and cancer cell-line models. TBKBP1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TBKBP1 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, TBKBP1 RNA expression shows 18,347 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, LIHC, and TGCT as cancer lineages where TBKBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBKBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBKBP1 survival associations across molecular data types. TBKBP1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBKBP1 RNA expression–survival associations across cancer types. High TBKBP1 expression shows unfavorable associations in MESO, ACC, KIRC and KICH, but favorable associations in PAAD and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TBKBP1 RNA expression.
This table summarizes TBKBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TBKBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBKBP1 shows lower tumor expression in BRCA, BLCA and UCEC and higher tumor expression in LIHC, KIRP and CHOL. The LIHC box plot shows higher TBKBP1 RNA expression in tumor versus normal tissue (log2 FC = +1.384, t-test p < 0.001).
This table shows molecular features associated with TBKBP1 in patient tissues and cancer cell lines. In patient samples, TBKBP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TBKBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
